-- ベル・フィナンシャル・グループ(ASX:BFG)は、4月30日までの4ヶ月間の税引後純利益(NPAT)が前年同期比197%増の1,630万豪ドル(監査未実施)となり、売上高は37%増の1億960万豪ドルとなったと、木曜日にオーストラリア証券取引所に提出した報告書で発表した。 報告書によると、好調な業績は、堅調な市場取引と取引活動、そしてプラットフォームの継続的な成長によって牽引された。特に、2025年上半期の低迷から下半期にかけて取引環境が回復したことで、業績は著しく改善した。 報告書によると、最初の4ヶ月間の市場売上高は前年同期比62%増の7,350万豪ドル、NPATは423%増の740万豪ドルだった。一方、プラットフォーム売上高は9%増の3,320万豪ドル、NPATは15%増の890万豪ドルだった。 同社の株価は、直近の木曜日の取引で6%上昇した。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.